Literature DB >> 24943696

Psychiatric adverse effects of pediatric corticosteroid use.

Linda B Drozdowicz1, J Michael Bostwick2.   

Abstract

Corticosteroids, highly effective drugs for myriad disease states, have considerable neuropsychiatric adverse effects that can manifest in cognitive disorders, behavioral changes, and frank psychiatric disease. Recent reviews have summarized these effects in adults, but a comprehensive review on corticosteroid effects in children has not been published since 2005. Here, we systematically review articles published since then that, we find, naturally divide into 3 main areas: (1) chronic effects of acute prenatal and neonatal exposure associated with prematurity and congenital conditions; (2) immediate behavioral effects of acute exposure via oncological protocols; and (3) acute behavioral effects of sporadic use in children and adolescents with other conditions. PsycInfo, MEDLINE, Embase, and Scopus were queried to identify articles reporting psychiatric adverse effects of corticosteroids in pediatric patients. Search terms included corticosteroids, adrenal cortex hormones, steroid psychosis, substance-induced psychoses, glucocorticoids, dexamethasone, hydrocortisone, prednisone, adverse effects, mood disorders, mental disorders, psychosis, psychotic, psychoses, side effect, chemically induced, emotions, affective symptoms, toxicity, behavior, behavioral symptoms, infant, child, adolescent, pediatric, paediatric, neonatal, children, teen, and teenager. Following guidelines for systematic reviews from the Potsdam Consultation on Meta-Analysis, we have found it difficult to draw specific conclusions that are more than general impressions owing to the quality of the available studies. We find a mixed picture with neonates exposed to dexamethasone, with some articles reporting eventual deficits in neuropsychiatric functioning and others reporting no effect. In pediatric patients with acute lymphoblastic leukemia, corticosteroid use appears to correlate with negative psychiatric and behavioral effects. In children treated with corticosteroids for noncancer conditions, adverse effects have been observed both during treatment and after cessation, although the data from article to article are not consistent enough to establish dose relationships. By and large, inhaled corticosteroids are considered safe and free of severe neuropsychiatric effects. Although both antipsychotic medications and benzodiazepines have been used to treat corticosteroid-induced mania and psychosis, no unified management strategy has emerged. Large-scale standardized investigations are needed to clarify the psychiatric effect of corticosteroids on children in all these conditions. Meanwhile, there is general agreement that patients as well as caregivers should be warned of the potential for behavioral adverse effects when patients receive these drugs.
Copyright © 2014 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24943696     DOI: 10.1016/j.mayocp.2014.01.010

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  19 in total

1.  Neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia treated on contemporary treatment protocols: A systematic review.

Authors:  Yin Ting Cheung; Kevin R Krull
Journal:  Neurosci Biobehav Rev       Date:  2015-04-07       Impact factor: 8.989

Review 2.  Recalcitrant Staphylococcus aureus Infections: Obstacles and Solutions.

Authors:  Sarah E Rowe; Jenna E Beam; Brian P Conlon
Journal:  Infect Immun       Date:  2021-03-17       Impact factor: 3.441

Review 3.  Steroids in pediatric acute respiratory distress syndrome.

Authors:  Nicolás Monteverde-Fernández; Federico Cristiani; Jenniffer McArthur; Sebastián González-Dambrauskas
Journal:  Ann Transl Med       Date:  2019-10

4.  Adenosine A2A receptor regulation of microglia morphological remodeling-gender bias in physiology and in a model of chronic anxiety.

Authors:  L Caetano; H Pinheiro; P Patrício; A Mateus-Pinheiro; N D Alves; B Coimbra; F I Baptista; S N Henriques; C Cunha; A R Santos; S G Ferreira; V M Sardinha; J F Oliveira; A F Ambrósio; N Sousa; R A Cunha; A J Rodrigues; L Pinto; C A Gomes
Journal:  Mol Psychiatry       Date:  2016-10-11       Impact factor: 15.992

5.  The impact of peer victimization and psychological symptoms on quality of life in children and adolescents with systemic lupus erythematosus.

Authors:  Selcuk Uzuner; Sezgin Sahin; Gizem Durcan; Amra Adrovic; Kenan Barut; Ali Guven Kilicoglu; Ayhan Bilgic; Kayhan Bahali; Ozgur Kasapcopur
Journal:  Clin Rheumatol       Date:  2017-04-27       Impact factor: 2.980

6.  Adenosine A2A receptors blockade attenuates dexamethasone-induced alterations in cultured astrocytes.

Authors:  Daniela Madeira; Liliana Dias; Patrícia Santos; Rodrigo A Cunha; Paula Agostinho; Paula M Canas
Journal:  Purinergic Signal       Date:  2022-04-27       Impact factor: 3.950

7.  Chemotherapy Pharmacodynamics and Neuroimaging and Neurocognitive Outcomes in Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia.

Authors:  Kevin R Krull; Yin Ting Cheung; Wei Liu; Slim Fellah; Wilburn E Reddick; Tara M Brinkman; Cara Kimberg; Robert Ogg; Deokumar Srivastava; Ching-Hon Pui; Leslie L Robison; Melissa M Hudson
Journal:  J Clin Oncol       Date:  2016-06-06       Impact factor: 44.544

Review 8.  Adrenal fatigue does not exist: a systematic review.

Authors:  Flavio A Cadegiani; Claudio E Kater
Journal:  BMC Endocr Disord       Date:  2016-08-24       Impact factor: 2.763

Review 9.  Function and Dysfunction of Microglia during Brain Development: Consequences for Synapses and Neural Circuits.

Authors:  Rosa C Paolicelli; Maria T Ferretti
Journal:  Front Synaptic Neurosci       Date:  2017-05-10

Review 10.  Rationale for Prolonged Glucocorticoid Use in Pediatric ARDS: What the Adults Can Teach Us.

Authors:  Andreas Schwingshackl; Gianfranco Umberto Meduri
Journal:  Front Pediatr       Date:  2016-06-14       Impact factor: 3.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.